ClinicalTrials.gg
Sign In
Drug

Zuberitamab clinical trials

studies test it
9
open now
7
in phase 3
2
first study started
2016

How each study uses zuberitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the zuberitamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Zuberitamab
5
Zuberitamab 1000mg
2

Studies by the year they started

9 studies that test it; most in 2026 (5)

Studies that test zuberitamab, by start year
YearStudies
20161
20241
20252
20265

By phase

A phase 1/2 study counts in both.

Phase 2
6
Phase 3
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Lymphoma, Large B-Cell, Diffuse
1
Nephrotic Syndrome
1
Epstein-Barr Virus Infections
1
Lymphoma, Follicular
1
Lymphoma, Mantle-Cell
1

Who runs them

Industry 3 · Other 6

BioRay Pharmaceutical Co., Ltd. (2) · Zhejiang Hisun Pharmaceutical Co. Ltd. (1) · Children's Hospital of Fudan University (1) · Ou Bai, MD/PHD (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Li Zhiming (1) · Sun Yat-sen University (1) · Peking University Third Hospital (1)

Often tested with

Tested in the same studies.

Orelabrutinib (2) · Cyclophosphamide (2) · Polatuzumab vedotin (2) · R-CHOP Regimen (1) · Pola-R-CHP Regimen (1) · R-mini-CHOP Regimen (1) · Rituximab (1) · Glofitamab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test zuberitamab.

Studies

Open first, then newest update. How each study uses zuberitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Given beside what is tested · 1 — zuberitamab is usual care or a partner of the new treatment

Codes

What other systems call zuberitamab · ClinicalTrials.gg INT017525

  • UNII (FDA) P1DFX74SQ8ZUBERITAMABOne source FDA
  • NCI Thesaurus C174825ZuberitamabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.